Czy można popijać leki sokiem grejpfrutowym?

• Authors: Zdrojewicz Zygmunt , Pachura Ewelina , Pachura Paulina

Title variants

EN

Is it possible to administer grapefruit juice with medicaments?

• Languages of publication: PL

Abstracts

PL

W ostatniej dekadzie bardzo duże zainteresowanie lekarzy praktyków i naukowców wzbudziło, dokonane zupełnie przez przypadek, odkrycie znaczącego wpływu spożywanego powszechnie soku z owocu grejpfruta na biodostępność, farmakokinetykę i dynamikę wielu, powszechnie przepisywanych leków. Dzieje się to za sprawą unikatowej zdolności soku z tego owocu do hamowania cytochromu P450 3A4 i kluczowego enzymu, występującego głównie w ścianie jelita i w wątrobie, a biorącego udział w metabolizmie substancji endo- i egzogennych. Efekt ten występuje jednak tylko w przypadku leków podawanych doustnie razem z ekstraktem z grejpfruta. Nie obserwuje się go, jeśli te same leki podamy drogą parenteralną. Artykuł ten powstał w celu analizy wpływu związków zawartych w grejpfrucie na metabolizm poszczególnych leków, najczęściej przepisywanych przez lekarzy rodzinnych. Interakcja ta, zwłaszcza w przypadku leków kardiowaskularnych i o wąskim zakresie terapeutycznym, jest na tyle znacząca, że wymaga szerszej edukacji, w tym aspekcie lekarzy praktyków, aby ci z kolei potrafili informować swoich pacjentów o prawidłowej administracji poszczególnych medykamentów.

Recently, drug interactions with grapefruit juice (GFJ) have received considerable attention from basic scientists, physicians, industry and drug regulatory agencies. GFJ has been shown to inhibit cytochrome P450 3A4 isoenzyme and P-glycoprotein transporters in the intestine and liver. The GFJ-induced inhibitory effects are considered to be responsible for alterations in drug bioavailability, and pharmacokinetic and pharmacodynamic changes when drugs are ingested concurrently with GFJ. However, little or no interaction is observed when GFJ is taken concomitantly with parentally administered drugs. Therefore, health care professionals and the public need to be advised of the potential risks associated with the concomitant use of GFJ and interacting medications, especially cardiovascular drugs and agents with a narrow therapeutic index. Physicians should give due consideration to the adjustment of dosages of interacting drugs or advise patients about proper administrations of certain drugs.

Keywords

EN

grapefruit, medicaments, fumarocumarin

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2014
• Issue: 1
• Pages: 51-56

Contributors

author

Zdrojewicz Zygmunt

author

Pachura Ewelina

author

Pachura Paulina

References

• So FV, Guthrie N, Chambers AF, et al. Inhibition of human cancer cell proliferation and delay of mammary cell tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996; 26: 167–181.
• Guthrie N, Carol KK. Inhibition of mammary cancer by citrus flavanoids. Adv Exp Med Biol 1998; 439: 227–236.
• Cerda JJ , Normann SJ, Sullivan MP, et al. Inhibition of atherosclerosis by dietary pectin in microswine with sustained hypercholesterolemia.Circulation 1994; 89: 1247–1253.
• Levy RH , Thummel KE, Trager WF, et al. Metabolic drug interactions. Philadelphia: PA: Lippincott Williams & Wilkins; 2000.
• Bailey DG , Spence JD , Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12:357–362.
• Guo LQ, Fukuda K, Ohta T, et al. Role of furanocoumarin derivatives on grapefruit juice – mediated inhibition of human CY P3A activity. Drug Metab Dispos 2000; 28: 766–771.
• Health Canada is advising Canadians not to take certain drugs with grapefruit juice. Ottawa: Health Canada; 2002 Jun 21.Available: www.hc- sc.gc.ca/english/protection/warnings/2002/2002_49e .htm (accessed 2002 Jul 9).
• Kane G, Lipsky J. Drug–grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933–942.
• Lundahl J, Regardh CG , Edgar B, et al. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 1998; 54: 75–81.
• Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P450. Drug Metab Dispos 1999; 27: 804–809.
• Lundahl J, Regardh CG , Edgar B, et al. Effects of grapefruit juice ingestion-pharmacokinetics and hemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 25: 139–145.
• Kivisto KT, Lamberg TS, Kantola T, et al. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.Clin Pharmacol Ther 1997; 62: 348–354
• Bailey DG , Dresser GK. Interaction between grapefruit juice and cardiovascular drugs. Am J Cadriovasc Drugs 2004; 4:281–297.
• Schmucker DL . Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18: 837–851.
• Bourian M, Runkel M, Krisp A, et al. Naringenin and interindividual variability in interaction of coumarin with grapefruit juice.Exp Toxicol Pathol 1999; 51: 289–293.
• Drug administration and grapefruit juice. In: Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmicists Association; 2001: L63–L65.
• Dresser GK, Bailey DG , Carruthers SG. Grapefruit juice – felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68:
• Bailey DG , Arnold JM , Strong HA , et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54: 589–594.
• Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000; 67: 201–214.
• Fuhr U, Muller-Peltzer H, Kern R, et al. Effect of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 2002; 58: 45–53.
• Libersa CC , Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49: 373–378.
• Bailey DG , Dresser GK, Kreeft JH , et al. Grapefruit–felodipine interaction: effect of unprocessed fruit and probable active ingredients.Clin Pharmacol Ther 2000; 68: 468–477.
• Kupferschmidt HH , Fattinger KE, Ha HR , et al. Grapefruit juice enhances the bioavailability of the HI V protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355–359.
• Goldstein PE, Boom A, van Geffel J, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch 1999; 437: 652–660.
• Ducharme MP, Warbasse LH , Edwards DJ . Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485–491.
• Andersen V, Pedersen N, Larsen NE , et al. Intestinal first pass metabolism of midazolam in liver cirrhosis – effect of grapefruit juice. Br J Clin Pharmacol 2002; 54: 120–124.
• Vanakoski J, Mattila MJ , Seppala T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 1996; 50: 501–508.
• Yasui N, Kondo T, Furukori H, et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 2000; 150: 185–190.
• Offman EM , Freeman DJ , Dresser GK, et al. Red wine – cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001; 70: 17–23.
• Van den Anker JN , de Wildt SN. Excessive terfenadine level due to drinking grapefruit juice. Ned Tijdschr Geneeskd 1997;141: 1976–1978.
• Le Goff-Klein N, Koffel JC , Jung L, et al. In vitro inhibition of simvastatin metabolism, a HMG -CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice. Eur J Pharm Sci 2003; 18: 31–35.
• Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.Clin Pharmacol Ther 1998; 63: 397–402.